Who owns the patent for Humira?

Who owns the patent for Humira?

I-MAK in 2018 found AbbVie filed 247 patent applications for Humira and won patents that could have protected the medicine for up to 39 years.

Is Humira still on patent?

The strengthened patent shield has stretched AbbVie’s legal monopoly in the U.S. for six years beyond the expiration of Humira’s main patent in 2016.

When was Humira patented?

1) High Certainty: US Patents for HUMIRA Derived from Brand-Side Litigation

Applicant Tradename Approval Date
Abbvie Inc. HUMIRA 04/21/2017
Abbvie Inc. HUMIRA 04/24/2013
Abbvie Inc. HUMIRA 04/21/2017
>Applicant >Tradename >Approval Date

Does Abbott make Humira?

Abbott’s HUMIRA┬« (adalimumab) Receives U.S. FDA Approval for the Treatment of Adult Patients with Moderate to Severe Ulcerative Colitis – Sep 28, 2012.

How many patents are there on Humira?

There are more than 100 patents on Humira. Most companies are not in a position to pursue such a broad patent portfolio, said Brougher, adding it is unlikely such an action or activity will be seen on every biological drug.

How many patents cover Humira?

Humira’s 247 patent applications in the U.S. more than triple those in Europe, and almost quadruple those in Japan. If Humira were a standalone company, it would be larger than many Fortune 500 companies, including Visa, General Mills, and Monsanto.

Why is Humira not generic?

Many drugs that treat rheumatoid arthritis and Crohn’s disease, like Humira and Enbrel, are biologic drugs, which means that they are made out of living cells. This makes them notoriously difficult to replicate exactly, which is what you would need to do to make generic options for people trying to save.

Is Abbott and AbbVie the same?

AbbVie was founded in 2013 when we became a separate company from Abbott. Our name represents a proud connection to that legacy.

Why is there no generic for Humira?

When did Humira patent expire in EU?

October 16, 2018
On October 16, 2018, product-specific patent protection on Humira® (extended with a supplementary protection certificate and an additional 6 months of pediatric exclusivity) came to an end in most European Union (EU) countries, 15 years after the initial marketing authorization (Storz, 2017).

How long is Humira patent?

Key patent expiration: 2023 Ever since AbbVie inked its first Humira biosimilar settlement with Amgen back in September 2017, the industry has had its eye on 2023.

What is the difference between AbbVie and Abbott?

The new Abbott Laboratories would specialize in diversified products including medical devices, diagnostic equipment and nutrition products, while AbbVie would operate as a research-based pharmaceutical manufacturer.

How long is the patent on Humira?

What is the best biosimilar to Humira?

Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to, and interchangeable with (may be substituted for), its reference product Humira (adalimumab) for Cyltezo’s approved uses.

Is there a biosimilar to Humira?

Humira is approved for multiple indications, including ankylosing spondylitis, psoriatic arthritis, Crohn disease, ulcerative colitis, and rheumatoid arthritis, and individual biosimilars of Humira, such as Cyltezo and Amjevita, have been approved for many indications of the originator product.

WHO OWNS Abbott pharmaceuticals?

Abbott Laboratories is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is The Vanguard Group, Inc. with 8.4% of shares outstanding. Capital Research and Management Company is the second largest shareholder owning 8.3% of common stock, and BlackRock, Inc.